---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-005352"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:48:55.016872+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine

## Summary
- FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.
- FDA indicated proposed study could support approval if clinical endpoint used; company revising protocol accordingly.
- Patient enrollment targeted to begin in summer 2024 at three northeastern U.S. hospitals.
- Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis but not yet for babesiosis; estimated 47,000 patients/year in U.S.

## SEC filing metadata
- accession: 0001213900-24-005352
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/0001213900-24-005352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/ea191960-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-005352
- JSON: https://secwatch.observer/filing/0001213900-24-005352.json
- Plain text: https://secwatch.observer/filing/0001213900-24-005352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.